The 5 key players our Eosinophilic Esophagitis Treatment report profiles.
In the order our report profiles them, not ranked by sales. Each name opens the company's page with its public records.
| # | Company | Website | Our reports |
|---|---|---|---|
| 1 | Sanofi |
sanofi.com (opens in a new tab) | 1,386 reports |
| 2 | Regeneron Pharmaceuticals |
regeneron.com (opens in a new tab) | 429 reports |
| 3 | Takeda Pharmaceutical Company Ltd |
takeda.com (opens in a new tab) | 660 reports |
| 4 | Dr. Falk Pharma | — | 33 reports |
| 5 | Ellodi Pharmaceuticals | — | 33 reports |
Companies leading the most active studies found with this market's trial search, worldwide (key players included).
Source: ClinicalTrials.gov, Industry lead sponsors of active studies found with this market's trial search, worldwide. Retrieved 13 Nov 2026.
One report for each place. Each tile opens that place's report.
Compare all 33 places for Eosinophilic Esophagitis Treatment, with active trials
Company profiles, market shares and strategies come with the full report, with researched size, forecast, growth and segments.
Key players are our report's research. Other companies and trial counts come from free public records, each with its source. Acuitas market figures are not published on this page.